Cerebrospinal fluid proteomics in multiple sclerosis

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1854, Issue 7, 2015, Pages 746-756

  Kroksveen, Ann C ^a   Opsahl, Jill A ^a   Guldbrandsen, Astrid ^a   Myhr, Kjell Morten ^a,b   Oveland, Eystein ^a   Torkildsen, Ø ^a,b   Berven, Frode S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarker; Cerebrospinal fluid; Multiple sclerosis; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

CEREBROSPINAL FLUID; HUMAN; MULTIPLE SCLEROSIS; PROCEDURES; PROTEOMICS;

BIOLOGICAL MARKERS; BIOMARKERS; HUMANS; MULTIPLE SCLEROSIS; PROTEOMICS;

EID: 84939977409     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.12.013     Document Type: Review

References (174)

1. M. Bantscheff, S. Lemeer, M. Savitski, and B. Kuster Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present Anal. Bioanal. Chem. 404 2012 939 965
2. T. Brinker, E. Stopa, J. Morrison, and P. Klinge A new look at cerebrospinal fluid circulation Fluids Barrier CNS 11 2014 10
3. C.H. Polman, S.C. Reingold, B. Banwell, and M. Clanet Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria Ann. Neurol. 69 2011 292 302
4. A. Chodobski, B.J. Zink, and J.S. Chodobska CNS barriers in neurotrauma Vascular Mechanisms in CNS Trauma 2014
5. J.G. McComb Recent research into the nature of cerebrospinal fluid formation and absorption J. Neurosurg. 59 1983 369 383
6. H.L. Christensen, A.T. Nguyen, F.D. Pedersen, and H.H. Damkier Na(+) dependent acid-base transporters in the choroid plexus; insights from slc4 and slc9 gene deletion studies Front. Physiol. 4 2013 304
7. D.A. Rottenberg, J. Howieson, and M.D. Deck The rate of CSF formation in man: preliminary observations on metrizamide washout as a measure of CSF bulk flow Ann. Neurol. 2 1977 503 510
8. D.A. Rottenberg, M.D. Deck, and J.C. Allen Metrizamide washout as a measure of CSF bulk flow Neuroradiology 16 1978 203 206
9. T.H. Milhorat The third circulation revisited J. Neurosurg. 42 1975 628 645
10. W.M. Pardridge Drug transport in brain via the cerebrospinal fluid Fluids Barrier CNS 8 2011 7
11. H. Davson Formation and drainage of the cerebrospinal fluid Sci. Basis Med. Annu. Rev. 238-259 1966
12. A. Brodbelt, and M. Stoodley CSF pathways: a review Br. J. Neurosurg. 21 2007 510 520
13. J. Zhang Proteomics of human cerebrospinal fluid - the good, the bad, and the ugly Proteomics Clin. Appl. 1 2007 805 819
14. C.J. Sindic, M.P. Van Antwerpen, and S. Goffette The intrathecal humoral immune response: laboratory analysis and clinical relevance Clin. Chem. Lab. Med.: CCLM/FESCC 39 2001 333 340
15. E.J. Thompson Cerebrospinal fluid J. Neurol. Neurosurg. Psychiatry 59 1995 349 357
16. H. Reiber, and J.B. Peter Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs J. Neurol. Sci. 184 2001 101 122
17. H. Reiber Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics Restor. Neurol. Neurosci. 21 2003 79 96
18. A. Regeniter, J. Kuhle, M. Mehling, and H. Moller A modern approach to CSF analysis: pathophysiology, clinical application, proof of concept and laboratory reporting Clin. Neurol. Neurosurg. 111 2009 313 318
19. H. Reiber Dynamics of brain-derived proteins in cerebrospinal fluid Clin. Chim. Acta Int. J. Clin. Chem. 310 2001 173 186
20. D.B. Stanimirovic, and A. Friedman Pathophysiology of the neurovascular unit: disease cause or consequence? J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 32 2012 1207 1221
21. L. Chen, G. Elias, M.P. Yostos, and B. Stimec Pathways of cerebrospinal fluid outflow: a deeper understanding of resorption Neuroradiology 2014 (Epub ahead of print)
22. R.J. Bateman, L.Y. Munsell, X. Chen, D.M. Holtzman, and K.E. Yarasheski Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates J. Am. Soc. Mass Spectrom. 18 2007 997 1006
23. K.F. Roberts, D.L. Elbert, T.P. Kasten, and B.W. Patterson Amyloid-beta efflux from the central nervous system into the plasma Ann. Neurol. 76 2014 837 844
24. A. Zougman, B. Pilch, A. Podtelejnikov, and M. Kiehntopf Integrated analysis of the cerebrospinal fluid peptidome and proteome J. Proteome Res. 7 2008 386 399
25. X. Yuan, and D.M. Desiderio Proteomics analysis of prefractionated human lumbar cerebrospinal fluid Proteomics 5 2005 541 550
26. S. Pan, Y. Wang, J.F. Quinn, and E.R. Peskind Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach J. Proteome Res. 5 2006 2769 2779
27. J.P. Noben, D. Dumont, N. Kwasnikowska, and P. Verhaert Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry J. Proteome Res. 5 2006 1647 1657
28. A. Sickmann, W. Dormeyer, S. Wortelkamp, and D. Woitalla Identification of proteins from human cerebrospinal fluid, separated by two-dimensional polyacrylamide gel electrophoresis Electrophoresis 21 2000 2721 2728
29. G. Maccarrone, D. Milfay, I. Birg, and M. Rosenhagen Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry Electrophoresis 25 2004 2402 2412
30. P. Davidsson, S. Folkesson, M. Christiansson, and M. Lindbjer Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry Rapid Commun. Mass Spectrom. 16 2002 2083 2088
31. Y. Ogata, M.C. Charlesworth, and D.C. Muddiman Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid J. Proteome Res. 4 2005 837 845
32. B.R. Wenner, M.A. Lovell, and B.C. Lynn Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS J. Proteome Res. 3 2004 97 103
33. J. Xu, J. Chen, E.R. Peskind, and J. Jin Characterization of proteome of human cerebrospinal fluid Int. Rev. Neurobiol. 73 2006 29 98
34. S. Schutzer, T. Liu, B. Natelson, and T. Angel Establishing the proteome of normal human cerebrospinal fluid PLoS ONE 5 2010
35. A. Guldbrandsen, H. Vethe, Y. Farag, and E. Oveland In-depth characterization of the cerebrospinal fluid proteome displayed through the CSF Proteome Resource (CSF-PR) Mol. Cell. Proteomics 13 2014 3152 3163
36. C.E. Teunissen, A. Petzold, J.L. Bennett, and F.S. Berven A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking Neurology 73 2009 1914 1922
37. J. Zhang, D.R. Goodlett, E.R. Peskind, and J.F. Quinn Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid Neurobiol. Aging 26 2005 207 227
38. G.S. Baird, S.K. Nelson, T.R. Keeney, and A. Stewart Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array Am. J. Pathol. 180 2012 446 456
39. C.P. Chen, R.L. Chen, and J.E. Preston Age-related increase of prostaglandin D(2) synthase concentration and glycation in ovine cerebrospinal fluid Exp. Gerontol. 44 2009 639 645
40. O. Eeg-Olofsson, H. Link, and A. Wigertz Concentrations of CSF proteins as a measure of blood brain barrier function and synthesis of IgG within the CNS in 'normal' subjects from the age of 6 months to 30 years Acta Paediatr. Scand. 70 1981 167 170
41. C. Johanson, P. McMillan, R. Tavares, and A. Spangenberger Homeostatic capabilities of the choroid plexus epithelium in Alzheimer's disease Cerebrospinal Fluid Res. 1 2004 3
42. C.P. Chen, R.L. Chen, and J.E. Preston The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma Exp. Gerontol. 47 2012 323 328
43. C. Nilsson, F. Stahlberg, C. Thomsen, and O. Henriksen Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging Am. J. Physiol. 262 1992 R20 R24
44. E. Murillo-Rodriguez, F. Desarnaud, and O. Prospero-Garcia Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat Life Sci. 79 2006 30 37
45. D.G. Baker, T.M. Bertram, P.M. Patel, and D.A. Barkauskas Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe Psychoneuroendocrinology 38 2013 2378 2382
46. A. Moghekar, J. Goh, M. Li, M. Albert, and R.J. O'Brien Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort Arch. Neurol. 69 2012 246 250
47. A. Agorastos, R.L. Hauger, D.A. Barkauskas, and T. Moeller-Bertram Circadian rhythmicity, variability and correlation of interleukin-6 levels in plasma and cerebrospinal fluid of healthy men Psychoneuroendocrinology 44 2014 71 82
48. R.J. Bateman, G. Wen, J.C. Morris, and D.M. Holtzman Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker Neurology 68 2007 666 669
49. O. Nygaard, B. Langbakk, and B. Romner Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder Clin. Chem. 43 1997 541 543
50. E. Schiffer, E. Van Gessel, and Z. Gamulin Influence of sex on cerebrospinal fluid density in adults Br. J. Anaesth. 83 1999 943 944
51. A. Petzold Intrathecal oligoclonal IgG synthesis in multiple sclerosis J. Neuroimmunol. 262 2013 1 10
52. A. Harrer, H. Tumani, S. Niendorf, and F. Lauda Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy Mult. Scler. 19 2013 1209 1212 (Houndmills, Basingstoke, England)
53. H. Reiber, and P. Thiele Species-dependent variables in blood cerebrospinal fluid barrier for proteins J. Clin. Chem. Clin. Biochem. Zeitschrift fur klinische Chemie und klinische Biochemie 21 1983 199 202
54. S. Brandner, C. Thaler, P. Lewczuk, and N. Lelental Neuroprotein dynamics in the cerebrospinal fluid: intraindividual concomitant ventricular and lumbar measurements Eur. Neurol. 70 2013 189 194
55. E. Aasebo, J.A. Opsahl, Y. Bjorlykke, and K.M. Myhr Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome PLoS ONE 9 2014 e90429
56. C. May, J.A. Kaye, J.R. Atack, and M.B. Schapiro Cerebrospinal fluid production is reduced in healthy aging Neurology 40 1990 500 503
57. B. Weisner, and W. Bernhardt Protein fractions of lumbar, cisternal, and ventricular cerebrospinal fluid. Separate areas of reference J. Neurol. Sci. 37 1978 205 214
58. J. Labus, S. Hackel, L. Lucka, and K. Danker Interleukin-1beta induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain barrier model J. Neurosci. Methods 228 2014 35 45
59. H.B. Stolp, K.M. Dziegielewska, C.J. Ek, and M.D. Habgood Breakdown of the blood-brain barrier to proteins in white matter of the developing brain following systemic inflammation Cell Tissue Res. 320 2005 369 378
60. A. Petzold, L.T. Sharpe, and G. Keir Spectrophotometry for cerebrospinal fluid pigment analysis Neurocrit. Care. 4 2006 153 162
61. M.J. Wood, G. Dimeski, and A.M. Nowitzke CSF spectrophotometry in the diagnosis and exclusion of spontaneous subarachnoid haemorrhage J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 12 2005 142 146
62. C.J. Eskey, and C.S. Ogilvy Fluoroscopy-guided lumbar puncture: decreased frequency of traumatic tap and implications for the assessment of CT-negative acute subarachnoid hemorrhage AJNR Am. J. Neuroradiol. 22 2001 571 576
63. F.S. Berven, A.C. Kroksveen, M. Berle, and T. Rajalahti Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome Proteomics Clin. Appl. 1 2007 699 711
64. C.R. Jimenez, M. Koel-Simmelink, T.V. Pham, L. van der Voort, and C.E. Teunissen Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables Proteomics Clin. Appl. 1 2007 1385 1392
65. J.S. You, V. Gelfanova, M.D. Knierman, and F.A. Witzmann The impact of blood contamination on the proteome of cerebrospinal fluid Proteomics 5 2005 290 296
66. C. Hesse, H. Larsson, P. Fredman, and L. Minthon Measurement of apolipoprotein E (apoE) in cerebrospinal fluid Neurochem. Res. 25 2000 511 517
67. P. Lewczuk, G. Beck, H. Esselmann, and R. Bruckmoser Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides Clin. Chem. 52 2006 332 334
68. R.E. Ferguson, D.F. Hochstrasser, and R.E. Banks Impact of preanalytical variables on the analysis of biological fluids in proteomic studies Proteomics Clin. Appl. 1 2007 739 746
69. A. Kraut, M. Marcellin, A. Adrait, and L. Kuhn Peptide storage: are you getting the best return on your investment? Defining optimal storage conditions for proteomics samples J. Proteome Res. 8 2009 3778 3785
70. A. Perret-Liaudet, M. Pelpel, Y. Tholance, and B. Dumont Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis Clin. Chem. 58 2012 787 789
71. T. Rosenling, C.L. Slim, C. Christin, and L. Coulier The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF) J. Proteome Res. 8 2009 5511 5522
72. T. Rosenling, M.P. Stoop, A. Smolinska, and B. Muilwijk The impact of delayed storage on the measured proteome and metabolome of human cerebrospinal fluid Clin. Chem. 57 2011 1703 1711
73. G. Chow, and J.W. Schmidley Lysis of erythrocytes and leukocytes in traumatic lumbar punctures Arch. Neurol. 41 1984 1084 1085
74. S. Ranganathan, A. Polshyna, G. Nicholl, J. Lyons-Weiler, and R. Bowser Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling Clin. Proteomics 2 2006 91 101
75. A.H. Simonsen, J.M. Bahl, P.B. Danborg, and V. Lindstrom Pre-analytical factors influencing the stability of cerebrospinal fluid proteins J. Neurosci. Methods 215 2013 234 240
76. M. del Campo, B. Mollenhauer, A. Bertolotto, and S. Engelborghs Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update Biomark. Med 6 2012 419 430
77. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
78. C. Eckstein, S. Saidha, and M. Levy A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis J. Neurol. 259 2012 801 816
79. J. Noseworthy, and A. Compston Disease-modifying Treatments in Multiple Sclerosis 2006 Churchill Livingstone London
80. J. Kirk, J. Plumb, M. Mirakhur, and S. McQuaid Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination J. Pathol. 201 2003 319 327
81. B.D. Trapp, J. Peterson, R.M. Ransohoff, and R. Rudick Axonal transection in the lesions of multiple sclerosis N. Engl. J. Med. 338 1998 278 285
82. J.M. Frischer, S. Bramow, A. Dal-Bianco, and C.F. Lucchinetti The relation between inflammation and neurodegeneration in multiple sclerosis brains Brain 132 2009 1175 1189
83. T. Revesz, D. Kidd, A.J. Thompson, R.O. Barnard, and W.I. McDonald A comparison of the pathology of primary and secondary progressive multiple sclerosis Brain 117 Pt 4 1994 759 765
84. J.W. Prineas, E.E. Kwon, E.S. Cho, and L.R. Sharer Immunopathology of secondary-progressive multiple sclerosis Ann. Neurol. 50 2001 646 657
85. H. Lassmann, J. van Horssen, and D. Mahad Progressive multiple sclerosis: pathology and pathogenesis Nat. Rev. Neurol. 8 2012 647 656
86. H. Lassmann Relapsing-remitting and primary progressive MS have the same cause(s) - the neuropathologist's view: 1 Mult. Scler. 19 2013 266 267 (Houndmills, Basingstoke, England)
87. B. Serafini, B. Rosicarelli, R. Magliozzi, E. Stigliano, and F. Aloisi Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis Brain Pathol. 14 2004 164 174 (Zurich, Switzerland)
88. O. Torkildsen, C. Stansberg, S.M. Angelskar, and E.J. Kooi Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients Brain Pathol. 20 2010 720 729
89. H. Lassmann Pathology and disease mechanisms in different stages of multiple sclerosis J. Neurol. Sci. 333 2013 1 4
90. M. Khalil, C. Enzinger, C. Langkammer, and S. Ropele CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome Mult. Scler. 19 2013 436 442
91. M. Gunnarsson, C. Malmeström, M. Axelsson, and P. Sundström Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab Ann. Neurol. 69 2011 83 89
92. K. Hawker, P. O'Connor, M. Freedman, and P. Calabresi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial Ann. Neurol. 66 2009 460 471
93. O.W. Howell, C.A. Reeves, R. Nicholas, and D. Carassiti Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis Brain 134 2011 2755 2771
94. S.R. Choi, O.W. Howell, D. Carassiti, and R. Magliozzi Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis Brain 135 2012 2925 2937
95. G.R. Campbell, I. Ziabreva, A.K. Reeve, and K.J. Krishnan Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis Ann. Neurol. 69 2011 481 492
96. B. Hallgren, and P. Sourander The effect of age on the non-haemin iron in the human brain J. Neurochem. 3 1958 41 51
97. T. Lu, Y. Pan, S.Y. Kao, and C. Li Gene regulation and DNA damage in the ageing human brain Nature 429 2004 883 891
98. T. Kuhlmann, G. Lingfeld, A. Bitsch, J. Schuchardt, and W. Bruck Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 2002 2202 2212
99. E.C. Tallantyre, L. Bo, O. Al-Rawashdeh, and T. Owens Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease Brain 132 2009 1190 1199
100. A. Kutzelnigg, C.F. Lucchinetti, C. Stadelmann, and W. Bruck Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2005 2705 2712
101. M. Comabella, and X. Montalban Body fluid biomarkers in multiple sclerosis Lancet Neurol. 13 2014 113 126
102. C. Teunissen, T. Menge, A. Altintas, and J. Álvarez-Cermeño Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis Mult. Scler. 19 2013 1802 1809 (Houndmills, Basingstoke, England)
103. A. Kroksveen, J. Opsahl, T. Aye, R. Ulvik, and F. Berven Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics J. Proteome 74 2011 371 388
104. C. Teunissen, M. Koel-Simmelink, T. Pham, and J. Knol Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry Mult. Scler. 17 2011 838 850 (Houndmills, Basingstoke, England)
105. M.P. Stoop, V. Singh, L.J. Dekker, and M.K. Titulaer Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis PLoS ONE 5 2010 e12442
106. M.P. Stoop, V. Singh, C. Stingl, and R. Martin Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients J. Proteome Res. 12 2013 1101 1107
107. M. Comabella, M. Fernandez, R. Martin, and S. Rivera-Vallve Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis Brain 133 2010 1082 1093
108. J. Ottervald, B. Franzen, K. Nilsson, and L.I. Andersson Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers J. Proteomics 73 2010 1117 1132
109. B. Pulinx, R.M. Hupperts, M. Vogt, and J. ten Kate Detection of differential protein expression in cerebrospinal fluid of patients with multiple sclerosis through two-dimensional differential in gel electrophoresis Clin. Chem. Lab. Med. CCLM/FESCC 50 2012 1693 1695
110. Y. Jia, T. Wu, C.A. Jelinek, and B. Bielekova Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS) Clin. Proteomics 9 2012 9
111. A. Kroksveen, E. Aasebø, H. Vethe, and V. Van Pesch Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM J. Proteome 78 2013 312 325
112. A. Kroksveen, A. Guldbrandsen, C. Vedeler, and K. Myhr Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls Acta Neurol. Scand. Suppl. 2012 90 96
113. S. Schutzer, T. Angel, T. Liu, and A. Schepmoes Gray matter is targeted in first-attack multiple sclerosis PLoS ONE 8 2013
114. A. Dhaunchak, C. Becker, H. Schulman, and O. De Faria Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis Ann. Neurol. 71 2012 601 613
115. V. Harris, A. Diamanduros, P. Good, and E. Zakin Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis Neurobiol. Dis. 40 2010 331 339
116. Y. Li, Z. Qin, M. Yang, and Y. Qin Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients J. Cell. Biochem. 112 2011 1930 1937
117. M. Liguori, A. Qualtieri, C. Tortorella, and V. Direnzo Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration PLoS ONE 9 2014
118. N. Rifai, M. Gillette, and S. Carr Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat. Biotechnol. 24 2006 971 983
119. H.L. Zhang, X.M. Zhang, X.J. Mao, and H. Deng Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy Acta Neurol. Scand. 125 2012 129 135
120. F. Licastro, M. Mallory, L.A. Hansen, and E. Masliah Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype J. Neuroimmunol. 88 1998 105 110
121. L.M. Villar, J. Masjuan, P. Gonzalez-Porque, and J. Plaza Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis Ann. Neurol. 53 2003 222 226
122. C. Gangneux, M. Daveau, M. Hiron, and C. Derambure The inflammation-induced down-regulation of plasma Fetuin-A (alpha2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites Nucleic Acids Res. 31 2003 5957 5970
123. K.M. Dziegielewska, N.A. Andersen, and N.R. Saunders Modification of macrophage response to lipopolysaccharide by fetuin Immunol. Lett. 60 1998 31 35
124. H.P. Jersmann, I. Dransfield, and S.P. Hart Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages Clin. Sci. 105 2003 273 278
125. M. Ombrellino, H. Wang, H. Yang, and M. Zhang Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan Shock 15 2001 181 185
126. I.A. Scarisbrick, R. Linbo, A.G. Vandell, and M. Keegan Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration Biol. Chem. 389 2008 739 745
127. 43-induced encephalitis in mice J. Neurosci. 28 2008 10330 10338
128. S. Do Carmo, L.C. Levros Jr., and E. Rassart Modulation of apolipoprotein D expression and translocation under specific stress conditions Biochim. Biophys. Acta 1773 2007 954 969
129. B.V. Jensen, J.S. Johansen, and P.A. Price High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 9 2003 4423 4434
130. J.S. Johansen, M. Stoltenberg, M. Hansen, and A. Florescu Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity Rheumatology 38 1999 618 626
131. C.S. Diefenbach, Z. Shah, A. Iasonos, and R.R. Barakat Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer Gynecol. Oncol. 104 2007 435 442
132. M. Kucur, F.K. Isman, C. Balci, and B. Onal Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia Urol. Oncol. 26 2008 47 52
133. A. Mitsuhashi, H. Matsui, H. Usui, and Y. Nagai Serum YKL-40 as a marker for cervical adenocarcinoma Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./Esmo 20 2009 71 77
134. D.R. Flower, A.C. North, and C.E. Sansom The lipocalin protein family: structural and sequence overview Biochim. Biophys. Acta 1482 2000 9 24
135. E. Rassart, A. Bedirian, S. Do Carmo, and O. Guinard Apolipoprotein D Biochim. Biophys. Acta 1482 2000 185 198
136. C.Y. Hu, W.Y. Ong, R.K. Sundaram, C. Chan, and S.C. Patel Immunocytochemical localization of apolipoprotein D in oligodendrocyte precursor-like cells, perivascular cells, and pericytes in the human cerebral cortex J. Neurocytol. 30 2001 209 218
137. A. Navarro, J. Tolivia, A. Astudillo, and E. del Valle Pattern of apolipoprotein D immunoreactivity in human brain Neurosci. Lett. 254 1998 17 20
138. P.R. Provost, L. Villeneuve, P.K. Weech, and R.W. Milne Localization of the major sites of rabbit apolipoprotein D gene transcription by in situ hybridization J. Lipid Res. 32 1991 1959 1970
139. K.M. Smith, R.M. Lawn, and J.N. Wilcox Cellular localization of apolipoprotein D and lecithin: cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization J. Lipid Res. 31 1990 995 1004
140. W.Y. Ong, C.P. Lau, S.K. Leong, and U. Kumar Apolipoprotein D gene expression in the rat brain and light and electron microscopic immunocytochemistry of apolipoprotein D expression in the cerebellum of neonatal, immature and adult rats Neuroscience 90 1999 913 922
141. M.D. Ganfornina, S. Do Carmo, E. Martinez, and J. Tolivia ApoD, a glia-derived apolipoprotein, is required for peripheral nerve functional integrity and a timely response to injury Glia 58 2010 1320 1334
142. A. Navarro, C. Ordonez, E. Martinez, and C. Perez Apolipoprotein D expression absence in degenerating neurons of human central nervous system Histol. Histopathol. 23 2008 995 1001
143. L. Terrisse, J. Poirier, P. Bertrand, and A. Merched Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients J. Neurochem. 71 1998 1643 1650
144. M. Reindl, G. Knipping, I. Wicher, and E. Dilitz Increased intrathecal production of apolipoprotein D in multiple sclerosis J. Neuroimmunol. 119 2001 327 332
145. N. Gaiano, and G. Fishell The role of notch in promoting glial and neural stem cell fates Annu. Rev. Neurosci. 25 2002 471 490
146. Q.D. Hu, B.T. Ang, M. Karsak, and W.P. Hu F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation Cell 115 2003 163 175
147. G.R. John, S.L. Shankar, B. Shafit-Zagardo, and A. Massimi Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation Nat. Med. 8 2002 1115 1121
148. C.F. Brosnan, and G.R. John Revisiting Notch in remyelination of multiple sclerosis lesions J. Clin. Invest. 119 2009 10 13
149. L.S. Laursen, C.W. Chan, and C. ffrench-Constant An integrin-contactin complex regulates CNS myelination by differential Fyn phosphorylation J. Neurosci. 29 2009 9174 9185
150. G. Games Collaborative, M. Ban, D. Booth, and R. Heard Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans J. Neuroimmunol. 179 2006 108 116
151. S. Simpson Jr., L. Blizzard, P. Otahal, I. Van der Mei, and B. Taylor Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis J. Neurol. Neurosurg. Psychiatry 82 2011 1132 1141
152. M.T. Cantorna, and B.D. Mahon Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence Exp. Biol. Med. 229 2004 1136 1142
153. A. Raghuwanshi, S.S. Joshi, and S. Christakos Vitamin D and multiple sclerosis J. Cell. Biochem. 105 2008 338 343
154. D.D. Bikle, P.K. Siiteri, E. Ryzen, and J.G. Haddad Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels J. Clin. Endocrinol. Metab. 61 1985 969 975
155. D.D. Bikle, E. Gee, B. Halloran, and M.A. Kowalski Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein J. Clin. Endocrinol. Metab. 63 1986 954 959
156. J. Correale, M.C. Ysrraelit, and M.I. Gaitan Immunomodulatory effects of Vitamin D in multiple sclerosis Brain 132 2009 1146 1160
157. J. Smolders, P. Menheere, A. Kessels, J. Damoiseaux, and R. Hupperts Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis Mult. Scler. 14 2008 1220 1224
158. A.K. Sharma, A.E. Schultze, D.M. Cooper, and R.Y. Reams Development of a percutaneous cerebrospinal fluid collection technique in F-344 rats and evaluation of cell counts and total protein concentrations Toxicol. Pathol. 34 2006 393 395
159. E. Gianazza, D. Veber, I. Eberini, and F.R. Buccellato Cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid Biochem. J. 374 2003 239 246
160. L. Liu, and K. Duff A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse J. Vis. Exp. 21 2008 Nov 10 (pii: 960)
161. R. Nirogi, V. Kandikere, K. Mudigonda, and G. Bhyrapuneni A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system J. Neurosci. Methods 178 2009 116 119
162. T. Rosenling, A. Attali, T.M. Luider, and R. Bischoff The experimental autoimmune encephalomyelitis model for proteomic biomarker studies: from rat to human Clin Chim. Acta Int. J. Clin. Chem. 412 2011 812 822
163. J.S. Smith, T.E. Angel, C. Chavkin, and D.J. Orton Characterization of individual mouse cerebrospinal fluid proteomes Proteomics 14 2014 1102 1106
164. J.M. Lubieniecka, F. Streijger, J.H. Lee, and N. Stoynov Biomarkers for severity of spinal cord injury in the cerebrospinal fluid of rats PLoS ONE 6 2011 e19247
165. M.P. Stoop, T. Rosenling, A. Attali, and R.J. Meesters Minocycline effects on the cerebrospinal fluid proteome of experimental autoimmune encephalomyelitis rats J. Proteome Res. 11 2012 4315 4325
166. A. Denic, A.J. Johnson, A.J. Bieber, and A.E. Warrington The relevance of animal models in multiple sclerosis research Pathophysiol. Off. J. Int. Soc. Pathophysiol./ISP 18 2011 21 29
167. R.M. Ransohoff Animal models of multiple sclerosis: the good, the bad and the bottom line Nat. Neurosci. 15 2012 1074 1077
168. S.B. Simmons, E.R. Pierson, S.Y. Lee, and J.M. Goverman Modeling the heterogeneity of multiple sclerosis in animals Trends Immunol. 34 2013 410 422
169. L. Blanchet, A. Smolinska, A. Attali, and M.P. Stoop Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis BMC Bioinforma. 12 2011 254
170. T. Rosenling, M.P. Stoop, A. Attali, and H. van Aken Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis J. Proteome Res. 11 2012 2048 2060
171. D. Baron, A. Bihouee, R. Teusan, and E. Dubois MADGene: retrieval and processing of gene identifier lists for the analysis of heterogeneous microarray datasets Bioinformatics 27 2011 725 726
172. J.A. Blake, C.J. Bult, J.T. Eppig, and J.A. Kadin The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse Nucleic Acids Res. 42 2014 D810 D817
173. L. Martens, H. Hermjakob, P. Jones, and M. Adamski PRIDE: the proteomics identifications database Proteomics 5 2005 3537 3545
174. S.J. Li, M. Peng, H. Li, and B.S. Liu Sys-BodyFluid: a systematical database for human body fluid proteome research Nucleic Acids Res. 37 2009 D907 D912